Read by QxMD icon Read


Omar Abdel-Rahman
AIM: Pembrolizumab is a fully humanized anti-PD-1 agent currently approved for the treatment of advanced melanoma and pretreated non-small-cell lung cancer (NSCLC). OBJECTIVE: To assess the efficacy and safety of different dose schedules of pembrolizumab in the treatment of patients with advanced NSCLC and melanoma. Search method: MEDLINE database has been searched. Reference lists of original studies and review articles were checked for other related articles. SELECTION CRITERIA: Prospective clinical trials reporting the outcomes of more than one dose schedule of pembrolizumab in the treatment of advanced NSCLC and melanoma...
November 28, 2016: Immunotherapy
Uyanga Batbold, Dmytro O Butov, Galyna A Kutsyna, Narantsetseg Damdinpurev, Elena A Grinishina, Otgonbayar Mijiddorj, Mikola E Kovolev, Khaliunaa Baasanjav, Tatyana S Butova, Munkhburam Sandagdorj, Ochirbat Batbold, Ariungerel Tseveendorj, Erkhemtsetseg Chunt, Svetlana I Zaitzeva, Hanna L Stepanenko, Natalia I Makeeva, Igor V Mospan, Volodymyr S Pylypchuk, John L Rowe, Peter Nyasulu, Vichai Jirathitikal, Allen I Bain, Marina G Tarakanovskaya, Aldar S Bourinbaiar
AIM: Safer and shorter antituberculosis treatment (ATT) regimens represent the unmet medical need. PATIENTS & METHODS: The patients were randomly assigned into two arms: the first (n = 137) received once-daily sublingual honey lozenge formulated with botanical immunomodulator Immunoxel and the second (n = 132) received placebo lozenges along with conventional ATT. Immunoxel and placebo arms were demographically similar: 102 versus 106 had drug-susceptible TB; 28 versus 20 multidrug-resistant TB (MDR-TB); 7 versus 7 extensively drug resistant TB (XDR-TB); and 22 versus 20 TB-HIV...
November 21, 2016: Immunotherapy
Lidia Kovaleva, Shashikant Apte, Sharat Damodar, Vijay Ramanan, Svetlana Loriya, Jordi Navarro-Puerto, Ali Khojasteh
AIM: To assess safety and efficacy of a 10% intravenous immunoglobulin in patients with primary immune thrombocytopenic purpura (ITP). PATIENTS & METHODS: ITP patients in two multicenter studies (Trials A/B) were treated with 2 g/kg Flebogamma(®) 10% DIF (over 2-5 days) and were followed up to 1-3 months. RESULTS: 18 patients in Trial A and 58 in Trial B were enrolled (12 children in Trial B). The response rate (platelet count ≥50 × 10(9)/l) was 72...
November 7, 2016: Immunotherapy
Roxana S Dronca, Aaron S Mansfield, Sean S Park, Haidong Dong
No abstract text is available yet for this article.
October 27, 2016: Immunotherapy
Roger A Levy, Renato Guzman, Gilberto Castañeda-Hernández, Manuel Martinez-Vazquez, Guilherme Damian, Carlos Cara
Biologics are increasingly being used to modify the course of immune-mediated inflammatory diseases. Some main agents are monoclonal antibodies and a fusion-protein that target TNF. This group includes adalimumab, infliximab, certolizumab pegol, golimumab and etanercept. Although the efficacy of anti-TNFs is supported by numerous randomized clinical trials, their pharmacokinetics depend on many factors, in particular immunogenicity, which can cause marked and rapid clearance and a consequent decrease in efficacy...
October 14, 2016: Immunotherapy
(no author information available yet)
No abstract text is available yet for this article.
October 12, 2016: Immunotherapy
Lucia Signorini, Serena Delbue, Pasquale Ferrante, Marco Bregni
Colorectal cancer (CRC) is one of the most common malignancies throughout the world and the leading cause of cancer-related mortality in Western countries. Recent progress in CRC treatment options, such as surgery, chemotherapy, radiotherapy and target therapy, has improved the prognosis, but advanced disease with recurrence or distant metastasis is usually incurable and has an unfavorable prognosis. The introduction of immunotherapy-associated strategies, both active and passive, to the treatment of CRC aims to overcome the limits of classical treatments...
October 2016: Immunotherapy
Christina K Lettieri, Nicole Appel, Nicole Labban, Danielle M Lussier, Joseph N Blattman, Pooja Hingorani
Survival outcomes for osteosarcoma have plateaued since the 1980s, and patients with relapsed or refractory disease have a particularly dismal outcome. Treatment options for these patients are limited primarily due to the paucity of effective therapeutics. Immune therapies such as tumor vaccines and traditional antigen-targeted monoclonal antibodies have had limited success in solid tumors. The recent discovery of novel immune checkpoint blockade strategies and their success in adult cancers has revitalized the use of immunotherapy strategies for the treatment of solid tumors...
October 2016: Immunotherapy
Lucy M De La Cruz, Nadia F Nocera, Brian J Czerniecki
HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 response can predict response to neoadjuvant therapy, risk of recurrence and disease-free survival. Vaccines consisting of HER2-pulsed type I polarized dendritic cells (DC1) administered during ductal carcinoma in situ and early IBC can efficiently correct anti-HER2Th1 response and have clinical impact on the disease...
October 2016: Immunotherapy
Ronald J Fecek, Walter J Storkus
Dendritic cells (DCs) are potent inducers of adaptive immunity and their clinical use in cancer vaccine formulations remains an area of active translational and clinical investigation. Although cancer vaccines applied as monotherapies have had a modest history of clinical success, there is great enthusiasm for novel therapeutic strategies combining DC-based cancer vaccines with agents that 'normalize' immune function in the tumor microenvironment (TME). Broadly, these combination vaccines are designed to antagonize/remove immunosuppressive networks within the TME that serve to limit the antitumor action of vaccine-induced T cells and/or to condition the TME to facilitate the recruitment and optimal function and durability of vaccine-induced T cells...
October 2016: Immunotherapy
Soroush Alipour, Samaneh Zoghi, Nastaran Khalili, Armin Hirbod-Mobarakeh, Leisha A Emens, Nima Rezaei
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Several approaches of active and passive immunotherapy for EOC have been studied. The aim of this systematic review was to assess the clinical efficacy of specific immunotherapy in patients with EOC. We found 4524 references in seven databases and we included ten controlled clinical trials with 2285 patients with EOC reporting five active immunotherapeutic agents and three passive immunotherapies. Meta-analysis of six studies showed that overall there was not any significant difference in overall survival and recurrence-free survival between patients undergoing specific immunotherapy and those in control group...
October 2016: Immunotherapy
Charu Aggarwal
Squamous cell carcinoma of the head and neck (SCCHN) accounts for 3% of all cancers. Most patients present with locally advanced disease, where multimodality therapies are used with curative intent. Despite favorable early local treatment results, about one third of the patients will eventually develop metastatic disease. Immunotherapy offers a novel therapeutic strategy beyond cytotoxic chemotherapy, with initial approvals in melanoma and non-small-cell lung cancer. HPV-associated SCCHN is a distinct subset, with unique epidemiology and treatment outcomes...
October 2016: Immunotherapy
Jennifer H Choe, Brian J Andonian, Grace J Kim, April Ks Salama
No abstract text is available yet for this article.
October 2016: Immunotherapy
Nancy Gupta, Babita Agrawal, Rakesh Kumar
No abstract text is available yet for this article.
October 2016: Immunotherapy
Roland B Walter
No abstract text is available yet for this article.
October 2016: Immunotherapy
Richard L Wasserman, Isaac Melamed, Lisa Kobrynski, Jennifer Puck, Sudhir Gupta, Jennifer Doralt, Marlies Sharkhawy, Werner Engl, Heinz Leibl, David Gelmont, Leman Yel
AIM: To assess the long-term efficacy, safety and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HYQVIA(®); IGHy) in children aged <18 years. PATIENTS & METHODS: Patients with primary immunodeficiency diseases were included in the studies. IGHy was administered every 3 or 4 weeks. RESULTS: Validated acute serious bacterial infections were reported at 0.08/patient-year (four pneumonia episodes in three patients)...
October 2016: Immunotherapy
Albert Roger, Nathalie Depreux, Yanina Jurgens, Aina T Serra, Matthew D Heath, Gloria Garcia, Murray A Skinner
AIM: A 1-year follow-up study comparing the safety and tolerability of the dosing schedules, satisfaction and effectiveness of a novel microcrystalline tyrosine-adsorbed mite (Dermatophagoides pteronyssinus)-allergoid subcutaneous immunotherapy (Acarovac Plus™) in 30 adult patients (18-65 years) with allergic rhinitis and/or asthma. MATERIALS & METHODS: The effectiveness of the product was assessed by nasal provocation test measuring peak nasal inspiratory flow/symptoms, in vitro immunologic changes (IgE, IgG4 and IL-10) and Treatment Satisfaction Questionnaire for Medication...
October 2016: Immunotherapy
(no author information available yet)
No abstract text is available yet for this article.
September 2016: Immunotherapy
Daniele Lilleri, Giuseppe Gerna
Human cytomegalovirus (HCMV) represents the major viral complication after hematopoietic stem cell transplantation. HCMV infection may be controlled by the reconstituting immune system and remain subclinical or can lead to severe systemic and/or organ disease (mainly pneumonia and gastroenteritis) when immune reconstitution is delayed or impaired. In order to prevent the occurrence of HCMV disease, a prompt diagnosis of HCMV infection is mandatory. The adoption of pre-emptive therapy strategies guided by virological monitoring dramatically reduced the occurrence of HCMV disease...
September 2016: Immunotherapy
Francesco Panza, Vincenzo Solfrizzi, Davide Seripa, Bruno P Imbimbo, Madia Lozupone, Andrea Santamato, Rosanna Tortelli, Ilaria Galizia, Camilla Prete, Antonio Daniele, Alberto Pilotto, Antonio Greco, Giancarlo Logroscino
Pharmacological manipulation of tau protein in Alzheimer's disease included microtubule-stabilizing agents, tau protein kinase inhibitors, tau aggregation inhibitors, active and passive immunotherapies and, more recently, inhibitors of tau acetylation. Animal studies have shown that both active and passive approaches can remove tau pathology and, in some cases, improve cognitive function. Two active vaccines targeting either nonphosphorylated (AAD-vac1) and phosphorylated tau (ACI-35) have entered Phase I testing...
September 2016: Immunotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"